CB Insights
Technology Market Intelligence
Technology Market Intelligence
Public list: Pharma Startups (6570)
Brickell Biotech is a clinical-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of skin diseases. Brickell's development strategy includes: rapidly and cost effectively develop...Show all
Company (IPO / Went public)
Phone: 720-505-4755
5777 Central Avenue
Suite 102
Boulder, 80301
Colorado, United States
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Investor | Investor Type | Location | Participating Rounds |
|---|---|---|---|
| Palisade Capital Management | Asset/Investment Management | Fort Lee, New Jersey, United States | Series C, Debt, Series B, Series A |
| Amorepacific Ventures | Corporate Venture | South Korea | Series C, Series B |
| Charles Stiefel | Angel Investor (Individual) | Series C | |
| Paycheck Protection Program | Government | Washington, DC, United States | Loan |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Dp2 antagonist and uses thereof | Jan 05, 2011 | Jun 27, 2017 | Patent |
| Dp2 antagonist and uses thereof | Aug 25, 2014 | Feb 21, 2017 | Patent |
| Process for the synthesis of (2e, 4e, 6z, 8e)-8-(3,4-dihydronaphthalen-1(2h)-ylidene)-3,7-dimethylocta-2, 4, 6-trienoic acid | Mar 15, 2017 | Application | |
| Formulation for soft anticholinergic analogs | May 22, 2014 | Application |
